Vancouver, British Columbia, Canada, Oct. 23, 2003 (PRIMEZONE) -- We are pleased to announce that ProtoKinetix (OTCBB:PKTX) has arranged (through *Dr. Jean-Marie Dupuy) an extensive independent group of validation trials on the RECAF receptor site by European Hospital Georges Pompidou of Paris, France.
Upon completion, these trials will confirm the existence of a receptor site, unique to cancer cells, that binds the molecule alpha fetaprotein.
RECAF(TM) (Receptor Alpha Fetaprotein) is a carbohydrate molecule that is located on the surface of cancer cells. RECAF makes it possible to specifically target and treat cancer with antibodies to stop cancer growth without damaging healthy cells. RECAF technology is patented and owned by BioCurex, Inc. In order to develop a therapeutic product that targets only malignant cells, ProtoKinetix will develop antibodies that will be:
1. tested for specificity 2. humanized 3. converted into catalytic antibodies 4. retested for specificity 5. tested for efficacy
*Dr. Jean-Marie Dupuis is a world recognized medical scientist, formerly Medical Director of Pasteur Merieux Connaught.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward -looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.